Rivaroxaban reduces length of hospital stay in patients with symptomatic venous thromboembolism
The phase III EINSTEIN deep vein thrombosis (DVT) and EINSTEIN pulmonary embolism (PE) trials demonstrated the potential of oral rivaroxaban (Xarelto, Bayer) – 15 mg twice daily for 21 days, followed by 20 mg once daily – for the treatment of venous thromboembolism (VTE), a term that embraces DVT and PE. A subsequent study by van Bellen et al., published in Current Medical Research and Opinion in 2014, was undertaken to assess the length of initial hospitalisation in patients presenting with either symptomatic DVT or PE using hospitalisation records from these trials.
Simon Nye, HMPG
Cite this article
Date published: 2016-12-19
Full text views:
- There are currently no refbacks.
African Journal of Thoracic and Critical Care Medicine| Online ISSN: 2617-0205
Our Journals: South African Medical Journal | African Journal of Health Professions Education | South African Journal of Bioethics and Law | South African Journal of Child Health | Southern African Journal of Critical Care | African Journal of Thoracic and Critical Care Medicine| South African Journal of Obstetrics and Gynaecology |